Chardan Capital Markets Reiterates Buy on uniQure (QURE) Following New FDA Guidelines on Gene Therapy
Tweet Send to a Friend
Chardan Capital Markets reiterated a Buy rating and $50.00 price target on uniQure BV (NASDAQ: QURE) following the FDA commissioner's ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
